<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02075086</url>
  </required_header>
  <id_info>
    <org_study_id>ANGIOSWITCH2011</org_study_id>
    <nct_id>NCT02075086</nct_id>
  </id_info>
  <brief_title>Angiogenic Switch in Patients With Colorectal Cancer</brief_title>
  <acronym>ANGIOSWITCH</acronym>
  <official_title>Angiogenic Switch as Predictor of Response to Chemotherapy in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Hospital de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Hospital de Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A group of colorectal cancer (CRC) patients treated with chemotherapy and Bevacizumab (Bev)
      maintain the same sensitivity after progression to maintenance treatment because they remain
      dependent on VEGF angiogenic mediator, while other patients in whom there is an angiogenic
      switch (AS) become dependent on other angiogenic cytokines and become resistant to Bev
      chemotherapy combinations .
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Days from cycle one day one to progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>2 years</time_frame>
    <description>Feasibility of doing a clinical prospective trial with a measure od plasma citoquines.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy treatment with Xelox or Xeliri and bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xelox or Xeliri Bevacizumab</intervention_name>
    <description>Chemotherapy treatment</description>
    <arm_group_label>Chemotherapy treatment</arm_group_label>
    <other_name>Cytokines measure</other_name>
    <other_name>Angiogenic study</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of stage IV colorectal adenocarcinoma.

          -  Age ≥ 18 years .

          -  Measurable disease by RECIST criteria.

          -  Life expectancy ≥ 6 months.

          -  Candidate to receive treatment with first-line chemotherapy.

          -  Availability of tumor tissue.

        Exclusion Criteria:

          -  Patients who have received prior treatment with first-line chemotherapy for metastatic
             disease.

          -  Patients in whom there is contraindication to the administration of either drug used
             in the study: capecitabine, irinotecan, oxaliplatin or Bev.

          -  Patients receiving anticoagulant oral treatment.

          -  Patient with diagnosis of other malignancies within 5 years prior to diagnosis except
             basal cell carcinoma or cervical carcinoma · in situ. · The inclusion of patients with
             malignant disease diagnosed more than 5 years ago without recurrence in the previous 3
             years will be analyzed individually

          -  Patients with bone disease as the only manifestation of the disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Cubillo, MD PhaD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo Hospital de Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Integral oncológico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2011</study_first_submitted>
  <study_first_submitted_qc>February 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>March 13, 2015</last_update_submitted>
  <last_update_submitted_qc>March 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Grupo Hospital de Madrid</investigator_affiliation>
    <investigator_full_name>Sofia Perea, Director Clinical Trials Unit.</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>angiogenic switch</keyword>
  <keyword>plasma cytokines</keyword>
  <keyword>Colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

